POSTER INFORMATION

2012 Poster Winner
Present a Poster and Save $50!
Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by December 7, 2012.
Register online, or by phone, fax or mail. Please indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool. Please see below for more information.
Reasons you should present your research poster at this conference:
- Your poster will be exposed to our international delegation
- Receive $50 off your registration
- Your poster abstract will be published in our conference materials
- Automatically entered into poster competition
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes
Criteria for poster competition award selection:
- Well-presented scientific data
- Engaging presentation
- Poster presenter must be present during assigned poster session viewing time
NOTE:
- You must select ONE track for your poster. (Your poster selection must be concurrent with your registration selection, but it does not have to be the same.)
- Your poster will hang only for the duration of your selected track.
- Late posters will only be accepted if space allows. Late posters will not be included in conference materials.
Note: Posters should be portrait orientation, with maximum dimensions of
36 inches wide (3 feet) x 48 inches high (4 feet).
* CHI reserves the right to publish your poster title and abstract in various marketing materials and products.
Click here for poster instructions
2013 Confirmed Poster Titles Include:
A novel cell-penetrating peptide, BR2, for the efficient delivery of a scFv into cancer cells |
| AIMLinkTM-ed bispecific antibody provides pan-influenza A protection |
| An insertion sequence-free Escherichia coli useful as a host for the production of recombinant proteins |
| Antibody Engineering for Targeted Delivery |
| Antibody Purifications Using Automated Liquid Handling Systems |
| Automated De Novo Monoclonal Antibody Sequencing |
| Composition effects on isomerization rate of a high concentration mab |
| Degradation of Abnormal Prion Protein by a Hyper-Stable Protease |
| Development of a Stable Lyophilized Formulation and Delivery Device for a Mucosal Vaccine to Prevent Blinding Endemic Trachoma |
| Efficient AlphaLISA immunoassays for the detection and characterization of monoclonal antibody biotherapeutics |
| Engineering antibodies for better targeting |
| EpiCHO |
| Formulation Robustness: How to Model the Past to Predict the Future |
| Host optimization of E.coli for autoinduction |
| Improved protein drug and vaccine stabilization using Recombinant Human Albumin (rAlbumin Human USP-NF) |
| Innovative Transformation of Automated 2D Protein Purification. |
| New IMAC Media Enabling Purification of Histidine-Tagged Proteins Directly from Eukaryotic Cell Culture Supernatants |
| Novel Bioprocess Affinity Resins for the Capture of Antibody Fragments |
| Optimization of the freezing process for improved protein quality |
| Protein Stability Analysis Using Automated Chemical Denaturation |
| Quantification of Subvisible and Submicron Content in Therapeutic Protein Formulations by Resonant Mass Measurement |
| Screening and evaluation of anti-STAT3 aptide and its antitumor efficacy |
| The Use of Temperature Dependent Intrinsic Fluorescence for the Analysis of In-Process Stability of a Protein |
| Use of Dip and Read™ Anti-Human Fab-CH1 Biosensors for Rapid Quantitation and Kinetic Analysis of Human IgG Fab Fragments |